1
were detailed. In this section, the contents are accurate, up-to-date, and by avoiding much of the specialist terminology, written in a reader-friendly mode. In conclusion, anyone who requires a general awareness of the engineering and manufacturing for biotechnology in bioindustry will have reason to consult this book. Takeshi Omasa Dept of Biotechnology, Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita Osaka, 565-0871, Japan. e-mail: [email protected] Protein drugs come of age Recombinant Protein Drugs (Milestones in Drug Therapy Series) Edited by Peter Buckel. Birkhäuser Verlag, 2001. 210 DM (x + 207 pages) ISBN 3 7643 5904 8 The biotechnology revolution of the past 30 years has had a profound impact on the direction of pharmaceutical research and development. Advances in molecular biology and immunology permitted the description of diseases at the molecular level and provided new paradigms for rational drug development. In addition, these developments provided us with the tools for manipulation of biological macromolecules, such as proteins and nucleic acids, and their large-scale production as a new generation of drugs. However, the translation of the knowledge from ‘bench to bedside’ would have been difficult without the close partnership of academic laboratories with pharmaceutical industries and the emergence of new ‘University spin off ’ companies. Success of these endeavors is most evident in the significant number of currently approved recombinant protein drugs (>30) and in the growing list of therapeutic proteins awaiting regulatory approval (>300). Recombinant Protein Drugs celebrates these advances by offering a historical perspective on selected advances in protein drug discovery and development. The chapters are organized into four sections: (1) pioneers and business; (2) first generation protein drugs; (3) proteins with new functions: protein engineering; and (4) further improvement of protein drugs. The first two chapters narrate the ‘pioneer stories’ of the development of recombinant interferons and hepatitis B vaccine. The excitement of the new beginnings is captured including the marriage of academia with industry, and the scientific challenges of the early days are also highlighted. The first- generation protein drugs are illustrated by three reviews on clotting factors, colony stimulating factors and tissue plasminogen activator. These reviews are comprehensive and cover basic sciences and clinical applications. The third section provides a glimpse of the current research on second-generation protein drugs with a review on immunokines (fusion proteins of cytokines with single-chain antibodies capable of binding tumor-associated antigens). The last section presents the challenges in protein drug delivery with discussions on two diverse approaches: protein formulation and gene delivery. Formulation of proteins in biodegradable polymers is a viable approach to enhance its stability and favor desirable pharmacokinetics. However, gene therapy approaches aimed at achieving expression of the therapeutic protein by the target cells present major hurdles that need to be overcome before they can be used in clinical applications. The book is well organized and well written. Its greatest strength as well as its unique feature is the historical perspectives presented by the pioneering scientists. It also provides an excellent sampling of currently approved therapeutic proteins and future challenges in protein drug development. Obviously this book is not meant to serve as a compendium on therapeutic proteins. In view of this, the topics of choice for the first two sections are justified. However, a broader coverage of current approaches in development of second-generation protein drugs and their delivery would have been more appropriate for the third and fourth sections. Despite this limitation, Recombinant Protein Drugs makes excellent reading for health professionals and biomedical researchers, especially for those interested in pharmaceutical biotechnology research. John Samuel Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada, T6G 2N8. e-mail: [email protected] Proteins – an unfolding story From Protein Folding to New Enzymes Edited by Alan Berry and Sheena E. Radford. Portland Press, London, UK, 2001. £65.00 (156 pages) ISBN 1 85578 143 3 Protein folding and protein engineering are two vibrant areas of molecular biology and biophysics. The discovery of molecular chaperones that facilitate folding, the Nobel prize-winning prion hypothesis and the linking of protein misfolding with various diseases are just some of the recent exciting developments in these fields. Genome sequencing efforts have further stoked the furnaces that drive such research. This book touches on these and other areas. In April 2000, the Biochemical Society held its 68th symposium at the University of Leeds (Leeds, UK), an excellent conference by all accounts. The book takes its title from the symposium and its content from articles contributed by some of the speakers at the meeting. A review from Chris Dobson opens the book and a chapter on degradation of explosives by Neil Bruce concludes the book, as the editors put it, ‘with a bang’. In between are chapters on membrane proteins, prions, chaperones, molecular dynamics simulation, directed evolution, folding of helices and coiled coils. This wide-ranging book embraces several topics of intense current interest, with obvious relevance to the post- genomic era, important diseases and fundamental aspects of protein structure. Reflecting its origin, the book is a smorgasbord of contemporary molecular biology and biophysics, although some contributions have been more carefully prepared than others have. There are a few short chapters, a couple comprising a mere six pages of content between an abstract and some references. These rather thin sandwiches serve mainly as pointers to key references in the literature. Contributions to the book are pitched, primarily, to specialists, but the book is relatively readable and could certainly be recommended as a broad read to pique the interest of graduate students embarking on research in protein folding or protein engineering. However, it is not sufficiently substantial to challenge classics such as Creighton’s Protein Folding [1], which covered similar ground a decade ago but in greater depth. TRENDS in Biotechnology Vol.20 No.3 March 2002 http://tibtech.trends.com 132 Forum

Protein drugs come of age

Embed Size (px)

Citation preview

Page 1: Protein drugs come of age

were detailed. In this section, the contents

are accurate, up-to-date, and by avoiding

much of the specialist terminology, written

in a reader-friendly mode.

In conclusion, anyone who requires a

general awareness of the engineering and

manufacturing for biotechnology in

bioindustry will have reason to consult

this book.

Takeshi Omasa

Dept of Biotechnology, Graduate School ofEngineering, Osaka University, 2-1Yamadaoka, Suita Osaka, 565-0871, Japan.e-mail: [email protected]

Protein drugs come

of age

Recombinant Protein Drugs (Milestones in

Drug Therapy Series)

Edited by Peter Buckel. Birkhäuser Verlag,2001. 210 DM (x + 207 pages) ISBN 3 7643 5904 8

The biotechnology revolution of the past

30 years has had a profound impact on the

direction of pharmaceutical research and

development. Advances in molecular

biology and immunology permitted the

description of diseases at the molecular

level and provided new paradigms for

rational drug development. In addition,

these developments provided us with the

tools for manipulation of biological

macromolecules, such as proteins and

nucleic acids, and their large-scale

production as a new generation of drugs.

However, the translation of the knowledge

from ‘bench to bedside’would have been

difficult without the close partnership of

academic laboratories with pharmaceutical

industries and the emergence of new

‘University spin off ’ companies. Success of

these endeavors is most evident in the

significant number of currently approved

recombinant protein drugs (>30) and in

the growing list of therapeutic proteins

awaiting regulatory approval (>300).

Recombinant Protein Drugs celebrates

these advances by offering a historical

perspective on selected advances in

protein drug discovery and development.

The chapters are organized into four

sections: (1) pioneers and business;

(2) first generation protein drugs;

(3) proteins with new functions: protein

engineering; and (4) further improvement

of protein drugs. The first two chapters

narrate the ‘pioneer stories’ of the

development of recombinant interferons

and hepatitis B vaccine. The excitement of

the new beginnings is captured including

the marriage of academia with industry,

and the scientific challenges of the early

days are also highlighted. The first-

generation protein drugs are illustrated

by three reviews on clotting factors,

colony stimulating factors and tissue

plasminogen activator. These reviews are

comprehensive and cover basic sciences

and clinical applications. The third section

provides a glimpse of the current research

on second-generation protein drugs with a

review on immunokines (fusion proteins of

cytokines with single-chain antibodies

capable of binding tumor-associated

antigens). The last section presents the

challenges in protein drug delivery with

discussions on two diverse approaches:

protein formulation and gene delivery.

Formulation of proteins in biodegradable

polymers is a viable approach to enhance

its stability and favor desirable

pharmacokinetics. However, gene therapy

approaches aimed at achieving expression

of the therapeutic protein by the target

cells present major hurdles that need to be

overcome before they can be used in

clinical applications.

The book is well organized and well

written. Its greatest strength as well as its

unique feature is the historical

perspectives presented by the pioneering

scientists. It also provides an excellent

sampling of currently approved

therapeutic proteins and future

challenges in protein drug development.

Obviously this book is not meant to serve

as a compendium on therapeutic proteins.

In view of this, the topics of choice for the

first two sections are justified. However, a

broader coverage of current approaches in

development of second-generation protein

drugs and their delivery would have been

more appropriate for the third and fourth

sections. Despite this limitation,

Recombinant Protein Drugs makes

excellent reading for health professionals

and biomedical researchers, especially for

those interested in pharmaceutical

biotechnology research.

John Samuel

Faculty of Pharmacy and PharmaceuticalSciences, University of Alberta, Edmonton,AB, Canada, T6G 2N8.e-mail: [email protected]

Proteins – an unfolding

story

From Protein Folding to New Enzymes

Edited by Alan Berry and Sheena E. Radford.Portland Press, London, UK, 2001. £65.00(156 pages) ISBN 1 85578 143 3

Protein folding and protein engineering

are two vibrant areas of molecular biology

and biophysics. The discovery of molecular

chaperones that facilitate folding, the Nobel

prize-winning prion hypothesis and the

linking of protein misfolding with various

diseases are just some of the recent exciting

developments in these fields. Genome

sequencing efforts have further stoked the

furnaces that drive such research. This

book touches on these and other areas.

In April 2000, the Biochemical Society

held its 68th symposium at the University

of Leeds (Leeds, UK), an excellent

conference by all accounts. The book takes

its title from the symposium and its content

from articles contributed by some of the

speakers at the meeting. A review from

Chris Dobson opens the book and a chapter

on degradation of explosives by Neil Bruce

concludes the book, as the editors put it,

‘with a bang’. In between are chapters on

membrane proteins, prions, chaperones,

molecular dynamics simulation, directed

evolution, folding of helices and coiled

coils. This wide-ranging book embraces

several topics of intense current interest,

with obvious relevance to the post-

genomic era, important diseases and

fundamental aspects of protein structure.

Reflecting its origin, the book is a

smorgasbord of contemporary molecular

biology and biophysics, although some

contributions have been more carefully

prepared than others have. There are a few

short chapters, a couple comprising a mere

six pages of content between an abstract

and some references. These rather thin

sandwiches serve mainly as pointers to key

references in the literature. Contributions to

the book are pitched, primarily, to specialists,

but the book is relatively readable and

could certainly be recommended as a

broad read to pique the interest of

graduate students embarking on research

in protein folding or protein engineering.

However, it is not sufficiently substantial

to challenge classics such as Creighton’s

Protein Folding [1], which covered similar

ground a decade ago but in greater depth.

TRENDS in Biotechnology Vol.20 No.3 March 2002

http://tibtech.trends.com

132 Forum